Semaglutide Cuts Heavy Drinking in Landmark Lancet Trial

The study: A research team led by Dr. Anders Fink-Jensen at Copenhagen University Hospital published results May 2, 2026 in The Lancet from a 26-week randomized controlled trial of once-weekly semaglutide (Ozempic/Wegovy) vs. placebo in 108 adults with alcohol use disorder (AUD) and comorbid obesity. It is the largest trial of a GLP-1 receptor agonist for AUD to date.

What they found: Heavy drinking days decreased significantly more in the semaglutide group than in the placebo group over the 26-week period. An earlier 9-week phase 2 trial (48 participants, 71% female) published in early 2026 found that semaglutide reduced grams of alcohol consumed (β=−0.48, P=.01), peak breath alcohol concentration (β=−0.46, P=.03), drinks per drinking day (β=−0.41, P=.04), and weekly craving (β=−0.39, P=.01) — with effect sizes at 0.5mg/week that are comparable to or exceed those of FDA-approved AUD medications (naltrexone, acamprosate).

The mechanism: GLP-1 receptor agonists appear to modulate dopamine reward pathways, reducing the motivational salience of alcohol and other rewarding stimuli. This is the same mechanism proposed for the drug’s effects on food intake — and, increasingly, on drugs other than alcohol.

Broader signal: A March 2026 BMJ analysis of 600,000+ U.S. veterans found that GLP-1 users had a 14–25% lower risk of developing SUDs across alcohol, opioids, cannabis, cocaine, and nicotine — a cross-substance finding suggesting systemic reward-pathway modulation rather than a substance-specific effect.

What’s not yet there: The FDA has not approved any GLP-1 for AUD treatment. Semaglutide can be prescribed off-label, particularly for patients who already qualify (obesity, Type 2 diabetes), but cost ($800–$1,000/month list price) remains a significant access barrier. Phase 3 trials are the logical next step.

Why This Matters for People in Recovery

Alcohol use disorder kills roughly as many Americans annually as drug overdoses — approximately 105,000 alcohol-induced deaths recorded in 2022. FDA-approved treatments (naltrexone, acamprosate, disulfiram) are chronically underutilized. If semaglutide’s signal holds in phase 3, it would be the first genuinely new pharmacological option for AUD in over two decades — and one that many patients are already taking for other indications.

Learn about alcohol use disorder and treatment options → | Find treatment near you →